Thalassemia Market Size To Reach $1,430.1 Million By 2030

Thalassemia Market Growth & Trends

The global thalassemia market size is expected to be valued at USD 1,430.1 million by 2030, as per a new report by Grand View Research, Inc., exhibiting a CAGR of 7.8% from 2024 to 2030. Increase in demand for a universal cure, rise in awareness about the disease, and technological advancements are likely to increase the adoption of gene therapies. 

Thalassemia is a general term for a group of inheritable blood disorders, in which the body produces abnormal hemoglobin, resulting in the destruction of red blood cells. This ultimately leads to anemia. There are two main types of thalassemia: alpha-thalassemia and beta-thalassemia, the latter being more serious. Beta-thalassemia is a common autosomal recessive disorder worldwide and it is relatively rare in the U.S.

Increase in the incidence of thalassemia is anticipated to fuel market growth. Despite technological advancements, the unmet need for a reliable treatment option still exists. Treatment of thalassemia is mostly restricted to regular blood transfusions and iron chelation therapy. Drugs prescribed for thalassemia mostly cure symptoms and side effects such as anemia, iron overload, and vitamin deficiency. However, gene therapy is emerging as a reliable treatment option for the disease.

Prevalence of thalassemia is reported to increase gradually over the years across different regions. This can be attributed to population migration, intermarriages, and genetic and environmental factors prompting the condition and its implications.

 Request a free sample copy or view report summary: Thalassemia Market Report

Thalassemia Market Report Highlights

• The iron chelating drugs segment held the largest revenue share of 52.7% in 2023. Patients with thalassemia often require regular blood transfusions, which can lead to iron overload in the body.

• The beta thalassemia held the largest revenue share of 71.2% in 2023. Ongoing advancements in diagnostic techniques and treatment options for beta thalassemia have significantly improved patient outcomes.

• North America thalassemia market dominated the global market with a revenue share of 42.8% in 2023.

Thalassemia Market Segmentation

Grand View Research has segmented the global thalassemia market on the basis of treatment, type, and region:

Thalassemia Treatment Outlook (Revenue, USD Million, 2018 - 2030)

• Iron Chelating Drugs

• Erythyroid maturation agents

• Stem Cell therapy

• Others

Thalassemia Type Outlook (Revenue, USD Million, 2018 - 2030)

• Alpha Thalassemia

• Beta Thalassemia

Thalassemia Regional Outlook (Revenue, USD Million; 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Thalassemia Market

• CHIESI Farmaceutici S.p.A.

• Bristol-Myers Squibb Company

• Sun Pharmaceutical Industries Ltd.

• Cipla

• Fresenius Kabi AG

• Novartis Pharmaceuticals Corporation

• Apotex Inc.

• bluebird bio, Inc.

• Vertex Pharmaceuticals Incorporated